Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 4
1994 5
1995 3
1996 10
1997 34
1998 95
1999 91
2000 103
2001 97
2002 132
2003 173
2004 209
2005 181
2006 216
2007 187
2008 206
2009 183
2010 199
2011 192
2012 225
2013 233
2014 214
2015 255
2016 245
2017 259
2018 283
2019 269
2020 319
2021 315
2022 327
2023 350
2024 359
2025 51

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,448 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its h …
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Zhang N, Gordon ML. Zhang N, et al. Clin Interv Aging. 2018 Oct 11;13:1963-1970. doi: 10.2147/CIA.S159920. eCollection 2018. Clin Interv Aging. 2018. PMID: 30349215 Free PMC article. Review.
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China. ...We include Chinese clinical trials and other well-designed studies investigating donepezil or using donepezil as a positive control, in w
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China. ...We include
Lecanemab: Looking Before We Leap.
Burke JF, Kerber KA, Langa KM, Albin RL, Kotagal V. Burke JF, et al. Neurology. 2023 Oct 10;101(15):661-665. doi: 10.1212/WNL.0000000000207505. Epub 2023 Jul 21. Neurology. 2023. PMID: 37479527 Free PMC article.
Before adopting lecanemab, we need to know that lecanemab is not less effective, vastly more harmful, and 100 more costly than donepezil....
Before adopting lecanemab, we need to know that lecanemab is not less effective, vastly more harmful, and 100 more costly than donepezil
Lecanemab Questions.
Nadeau SE. Nadeau SE. Neurology. 2024 Apr 9;102(7):e209320. doi: 10.1212/WNL.0000000000209320. Epub 2024 Mar 14. Neurology. 2024. PMID: 38484213
The attenuation of change on the Alzheimer's Disease Assessment Scale-Cognitive 14 achieved by lecanemab at 18 months was 50% of that achieved by donepezil at 6 months. Lecanemab treatment imposes a high treatment burden. The fact that the burden commences at the initiatio …
The attenuation of change on the Alzheimer's Disease Assessment Scale-Cognitive 14 achieved by lecanemab at 18 months was 50% of that achiev …
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y. Fan F, et al. J Alzheimers Dis. 2022;85(3):1195-1204. doi: 10.3233/JAD-215423. J Alzheimers Dis. 2022. PMID: 34924395
The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear to be beneficial for cognitive, global performances, and activities of daily living in patients with AD. ...
The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear t …
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC. Veroniki AA, et al. BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012. BMJ Open. 2022. PMID: 35473731 Free PMC article.
RESULTS: Our IPD-NMA compared nine treatments (including placebo). Donepezil (mean difference (MD)=1.41, 95% CI: 0.51 to 2.32) and donepezil +memantine (MD=2.57, 95% CI: 0.07 to 5.07) improved MMSE score (56 RCTs, 11 619 participants; CINeMA score: moderate) compare …
RESULTS: Our IPD-NMA compared nine treatments (including placebo). Donepezil (mean difference (MD)=1.41, 95% CI: 0.51 to 2.32) and …
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and aging societies worldwide. Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. ...M …
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and …
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Bago Rožanković P, et al. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. Cogn Behav Neurol. 2021. PMID: 34851866 Clinical Trial.
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) are common in individuals with Alzheimer disease (AD). Donepezil and memantine are both widely used for the treatment of moderate AD. OBJECTIVE: To evaluate the effects of donepezil and memantine i …
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) are common in individuals with Alzheimer disease (AD). Donepezil
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Battle CE, et al. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2. Cochrane Database Syst Rev. 2021. PMID: 33704781 Free PMC article.
AUTHORS' CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Done
AUTHORS' CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have …
Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.
Chen Y, Lai M, Tao M. Chen Y, et al. Medicine (Baltimore). 2024 Apr 19;103(16):e37799. doi: 10.1097/MD.0000000000037799. Medicine (Baltimore). 2024. PMID: 38640313 Free PMC article.
Donepezil 5 mg and GV-971 900 mg did not increase the drug withdrawal rates due to various reasons or adverse reactions when compared to the placebo. Donepezil demonstrated superior binding to the protein and exhibited greater efficacy compared to other drugs. ...
Donepezil 5 mg and GV-971 900 mg did not increase the drug withdrawal rates due to various reasons or adverse reactions when compared
5,448 results